Clinical Trials Currently Conducted at NJRetina

Age-Related Macular Degeneration

GALLEGO-GR40973 (Sponsor: Roche/Genentech)
2019-present


NCT Number: NCT03972709

A Phase II, Multi-Center, Randomized, Single-Masked, Sham Injection Controlled Study of the Safety, Tolerability, and Evidence of Activity of Intravitreal Injection of R7171009 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

For more information, click here.

 

Age-Related Macular Degeneration

SPIAM-202 (Sponsor: Stealth)
2019-present


NCT Number: NCT03891875
A Phase II, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy and Pharmakinetics of Subcutaneous Injections of Elamipretide in Subjects with Age-Related Macular Degeneration with Geographic Atrophy

For more information, click here.

 

Age-Related Macular Degeneration

APL2-304 (Sponsor: Apellis)
2018-present


NCT Number: NCT03525613

A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

For more information, click here.

 

Age-Related Macular Degeneration

Tenaya GR40306 (Sponsor: Roche/Genentech)
2019-present


NCT Number: NCT03823287

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate R06867461 in Patients with Neovascular Age-Related Macular Degeneration

For more information, click here.

 

Diabetic Retinopathy

Robin (Sponsor: Boehringer Ingelheim)
2017-present


NCT Number: NCT03238963

A randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of orally administered BI 1467335 for 12 weeks with a 12 week follow up period in patients with nonproliferative diabetic retinopathy without center-involved diabetic macular edema

For more information, click here.

 

Age-Related Macular Degeneration

Panda KHB-1802 (Sponsor: Chengdu)
2018-present


NCT Number: NCT03630952

A Phase III, Multi-Center, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration

For more information, click here.

 

Diabetic Macular Edema

Yosemite- GR40349 (Sponsor: Roche/Genentech)
2018-present


NCT Number: NCT03622580

A Phase III, Multi-Center, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema

For more information, click here.

 

Age-Related Macular Degeneration

Archway Ranibizumab GR40548 (Sponsor: Roche/Genentech)
2018-present


NCT Number: NCT03677934

A Phase III, Multi-Center, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with NeoVascular Age-Related Macular Degeneration

For more information, click here.

 

Age-Related Macular Degeneration

Candela (Sponsor: Roche/Genentech)
2019-present


NCT Number: NCT04126317

A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration

For more information, click here.

Questions?
Contact us today! We’re here to help!

©All Rights Reserved. NJRetina 2020